Table 4.
Clinical parameters
| Total participants (N = 101) | |
|---|---|
| Spirometry assessment (most recent) | |
| Participants with assessment available, n (%) | 75 (75%) |
| Pre-BD FVC | 2.6 ± 0.8 |
| Post-BD FVC* | 2.7 ± 0.8 |
| Pre-BD % of the predicted FVC value | 83.4 ± 17.6 |
| Post-BD % of the predicted FVC value† | 82.9 ± 16.9 |
| Pre-BD FEV1 | 2.0 ± 0.7 |
| Post-BD FEV1‡ | 2.0 ± 0.7 |
| Pre-BD % of the predicted FEV1 value§ | 77.9 ± 20.7 |
| Post-BD % of the predicted FEV1 value† | 80.8 ± 18.9 |
| Pre-BD FEV1/FVC | 76.3 ± 11.2 |
| Post-BD FEV1/FVC‡ | 76.7 ± 10.9 |
| Blood test (at study visit) | |
| WBC (cells/mm3) | 7300.0 (6100.0, 8910.0) |
| Eosinophils (%) | 3.3 (1.7, 6.3) |
| Absolute eosinophils (cells/mm3) | 250.0 (110.0, 500.0) |
| Total serum IgE (IU/mL) | 99.5 (38.0, 289.0) |
Data are shown as mean ± SD or median (IQR) unless otherwise indicated
BD = bronchodilator; FEV = forced expiratory volume; FVC = forced vital capacity; GINA = Global Initiative for Asthma; SD = standard deviation, IQR = interquartile range (25th percentile, 75th percentile); WBC = white blood cell
*23/75 (31%) patients had missing values
†34/75 (45%) patients had missing values
‡24/75 (32%) patients had missing values
§1/75 (1%) patient had a missing value